<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-30306" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Anticholinergic Toxicity</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Broderick</surname>
            <given-names>Erin D.</given-names>
          </name>
          <aff>Campbell Un, Southeastern Regional MC</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Metheny</surname>
            <given-names>Heidi</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Crosby</surname>
            <given-names>Brianna</given-names>
          </name>
          <aff>Southeastern Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Erin Broderick declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Heidi Metheny declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Brianna Crosby declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>30</day>
          <month>4</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-30306.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Anticholinergic toxicity is commonly seen in the emergency department but is rarely fatal. According to the 2015 annual American Association of Poison Control Centers (AAPCC) report, there were just under 14,000 exposures reported to poison control centers that year, none of which led to mortality. However, in prior years, up to 51 cases have been reported as fatalities. This activity describes the causes, pathophysiology, and presentation and highlights the treatment and management of these patients.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the causes of anticholinergic toxicity.</p></list-item><list-item><p>Outline the presentation of a patient with anticholinergic toxicity.</p></list-item><list-item><p>Discuss the current treatment and management options for anticholinergic toxicity.</p></list-item><list-item><p>Summarize how an interprofessional team can coordinate care to provide the best outcomes in patients with anticholinergic toxicity.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30306">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-30306.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Anticholinergic toxicity is common in the emergency department but rarely fatal.<xref ref-type="bibr" rid="article-30306.r1">[1]</xref> According to the 2015 annual American Association of Poison Control Centers (AAPCC) report, there were just under 14,000 exposures reported to poison control centers that year, none of which lead to mortality.<xref ref-type="bibr" rid="article-30306.r1">[1]</xref> However, in prior years, up to 51 cases have been reported as deadly.<xref ref-type="bibr" rid="article-30306.r2">[2]</xref><xref ref-type="bibr" rid="article-30306.r3">[3]</xref><xref ref-type="bibr" rid="article-30306.r4">[4]</xref>&#x000a0;Overdoses of compounds with anticholinergic activity can be accidental or intentional. This is an important topic&#x000a0;as anticholinergics are readily accessible, and many medications have anticholinergic side effects. The mechanism of action of anticholinergic compounds is the antagonization of the neurotransmitter acetylcholine.&#x000a0; Many pharmaceuticals and substances found in plants contain anticholinergic activity.</p>
      </sec>
      <sec id="article-30306.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Substances with anticholinergic activity are used and misused extensively worldwide. Toxicity typically occurs secondary to an overdose of compounds with anticholinergic properties, although mild toxicity can even be seen as a side effect when the medication is taken appropriately. The vast majority of these agents are orally ingested.&#x000a0;The naturally occurring compounds atropine, hyoscyamine, and hyoscine are the prototypical anticholinergics from which others are synthesized. Atropine is an antidote for cholinergic toxicity from organophosphates and nerve agents and acute treatment of bradyarrhythmias.<xref ref-type="bibr" rid="article-30306.r5">[5]</xref></p>
        <p>Medications with anticholinergic properties include antidepressants, antihistamines, antiparkinson drugs, antipsychotics, antispasmodics, and mydriatics. Many medications&#x000a0;possess anticholinergic activity as their primary pharmacologic effect, while others exhibit these properties as adverse effects. Ingestion of multiple medications with anticholinergic properties is synergistic. This is&#x000a0;especially important for elderly patients on numerous medications.<xref ref-type="bibr" rid="article-30306.r6">[6]</xref><xref ref-type="bibr" rid="article-30306.r7">[7]</xref>&#x000a0;The most common source of an anticholinergic drug overdose is antihistamines.<xref ref-type="bibr" rid="article-30306.r1">[1]</xref></p>
        <p>Plants are also a common source of accidental and intentional anticholinergic ingestion.<xref ref-type="bibr" rid="article-30306.r8">[8]</xref> Plants that contain belladonna alkaloids are often abused due to their hallucinogenic properties.<xref ref-type="bibr" rid="article-30306.r9">[9]</xref>&#x000a0;Illicit drugs, including cocaine and heroin, have been known to be contaminated with anticholinergics such as hyoscine or atropine.<xref ref-type="bibr" rid="article-30306.r10">[10]</xref><xref ref-type="bibr" rid="article-30306.r11">[11]</xref><xref ref-type="bibr" rid="article-30306.r12">[12]</xref>&#x000a0;Toxicity has also been reported with topical application.<xref ref-type="bibr" rid="article-30306.r13">[13]</xref><xref ref-type="bibr" rid="article-30306.r14">[14]</xref></p>
      </sec>
      <sec id="article-30306.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>In 2015, there were approximately&#x000a0;14,000 anticholinergic exposures reported to poison control centers.<xref ref-type="bibr" rid="article-30306.r1">[1]</xref> The following year, there were 2,159,032 total cases of human exposure reported to poison control centers. Antihistamines were the sixth most frequently involved category of substances involved in human exposure at 4.19%.<xref ref-type="bibr" rid="article-30306.r15">[15]</xref> These figures probably grossly underestimate the total number of exposures, as many go unreported to poison control centers.</p>
      </sec>
      <sec id="article-30306.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Anticholinergic agents competitively block the binding of the neurotransmitter acetylcholine at muscarinic receptors. Anticholinergics cause minimal blockade at nicotinic receptor sites. Muscarinic acetylcholine receptors&#x000a0;are&#x000a0;located&#x000a0;in smooth muscle, the ciliary body of the eye, salivary glands, sweat glands, and the central nervous system (CNS). Muscarinic receptors are not found at the neuromuscular junction.<xref ref-type="bibr" rid="article-30306.r16">[16]</xref><xref ref-type="bibr" rid="article-30306.r17">[17]</xref><xref ref-type="bibr" rid="article-30306.r18">[18]</xref></p>
      </sec>
      <sec id="article-30306.s6" sec-type="Toxicokinetics">
        <title>Toxicokinetics</title>
        <p>Most anticholinergic agents are orally ingested, and their onset of action typically occurs within 2 hours.<xref ref-type="bibr" rid="article-30306.r19">[19]</xref>&#x000a0;Some topical agents, such as hyoscine, can have effects lasting for over 24 hours.<xref ref-type="bibr" rid="article-30306.r20">[20]</xref>&#x000a0;The effects of anticholinergic compounds on the&#x000a0;central nervous system (CNS) can last over 8 hours, while the effects on the cardiovascular system are generally much shorter.<xref ref-type="bibr" rid="article-30306.r21">[21]</xref></p>
      </sec>
      <sec id="article-30306.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>A thorough history and physical exam are critical to the identification of patients with anticholinergic poisoning. Patients may present with a history of intentional ingestion of common anticholinergic agents such as antihistamines or jimson weed; however, the history is often less straightforward.<xref ref-type="bibr" rid="article-30306.r8">[8]</xref> Patients may present after a suicide attempt and be unwilling or unable to disclose what they ingested. Young children may be brought in by a caretaker/parent with suspected ingestion of unknown etiology.</p>
        <p>The clinician must be familiar with the anticholinergic toxidrome as a reliable history is not always obtainable. The mnemonic &#x0201c;red as a beet, dry as a bone, blind as a bat, mad as a hatter, hot as a hare, full as a flask&#x0201d; is helpful to remember the classic signs and symptoms of anticholinergic poisoning. Respectively, these include flushing, anhydrosis, dry mucous membranes, mydriasis, altered mental status, fever, and urinary retention. Decreased bowel sounds are also a common physical exam finding. Central nervous system effects may include delirium, hallucinations, agitation, restlessness, confusion, staccato speech, and picking at clothing and bedding. Seizures and jerking movements are possible.<xref ref-type="bibr" rid="article-30306.r22">[22]</xref><xref ref-type="bibr" rid="article-30306.r23">[23]</xref>&#x000a0;Diphenhydramine, in particular,&#x000a0;has been reported to be associated with wide-complex tachycardia and QT prolongation.<xref ref-type="bibr" rid="article-30306.r24">[24]</xref><xref ref-type="bibr" rid="article-30306.r25">[25]</xref></p>
      </sec>
      <sec id="article-30306.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The clinician should utilize a standard approach to any suspected poisoned patient. As with any potentially critically ill patient, evaluation of the patient&#x02019;s airway, respiratory, and circulatory status should immediately be performed. Vital signs, including temperature, heart rate, respiratory rate, blood pressure,&#x000a0;and&#x000a0;oxygen saturation, should be obtained. The patient should be fully exposed to assess for topical sources of toxicity, such as a hyoscine patch. The patient should also be placed on continuous cardiac monitoring and have intravenous (IV) access established.&#x000a0;</p>
        <p>Diagnostics, including urinalysis, urine drug screen, finger-stick glucose, salicylate and acetaminophen levels, electrocardiogram, and pregnancy test for females, should be&#x000a0;obtained. If seizures or significant hyperthermia are present, the clinician should obtain further laboratory evaluation, including a metabolic panel, liver enzymes,&#x000a0;and creatine kinase. However, it is important to understand that anticholinergic toxicity is a clinical diagnosis. Anticholinergic toxicity can be confused with sympathomimetic toxicity. However, the absence of sweating indicates anticholinergic toxicity.<xref ref-type="bibr" rid="article-30306.r22">[22]</xref></p>
      </sec>
      <sec id="article-30306.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Supportive care is usually all that is required for the treatment of anticholinergic toxicity. The most difficult therapeutic challenge is treating the agitation that can be severe in patients with anticholinergic toxicity. Benzodiazepines administered intravenously should be the first-line therapy for agitation. This may require large doses but is necessary to avoid making symptoms such as hyperthermia and rhabdomyolysis worse. Physostigmine may be indicated in severe cases refractory to benzodiazepines.<xref ref-type="bibr" rid="article-30306.r26">[26]</xref>&#x000a0;IV fluids should be administered in the case of hypotension, or rhabdomyolysis is suspected. Cooling measures should be initiated if significant hyperthermia is present.<xref ref-type="bibr" rid="article-30306.r27">[27]</xref>&#x000a0;Activated charcoal should be considered if the ingestion occurred within one hour before the patient presents. However, administration somewhat outside this window may be appropriate, as anticholinergics decrease gastrointestinal motility.<xref ref-type="bibr" rid="article-30306.r28">[28]</xref><xref ref-type="bibr" rid="article-30306.r29">[29]</xref> If wide-complex dysrhythmias develop,&#x000a0;IV sodium bicarbonate should be administered.<xref ref-type="bibr" rid="article-30306.r25">[25]</xref><xref ref-type="bibr" rid="article-30306.r30">[30]</xref></p>
        <p>Physostigmine is usually only given in the case of both peripheral and central signs and symptoms of anticholinergic poisoning.<xref ref-type="bibr" rid="article-30306.r26">[26]</xref> Physostigmine is an acetylcholinesterase inhibitor active in both the central and peripheral nervous systems. Resuscitation equipment, including atropine, should be readily available before physostigmine is given. The recommended dose is 0.5 to 2 mg IV for adults and&#x000a0;0.02 mg/kg IV for pediatric patients, with a maximum pediatric dose of&#x000a0;0.5 mg.<xref ref-type="bibr" rid="article-30306.r31">[31]</xref>&#x000a0;Repeat&#x000a0;dosing&#x000a0;may be required after approximately 30 minutes if symptoms recur.<xref ref-type="bibr" rid="article-30306.r32">[32]</xref> In general, physostigmine is only recommended for pure anticholinergic poisoning.<xref ref-type="bibr" rid="article-30306.r33">[33]</xref>&#x000a0;Intravenous&#x000a0;fat emulsion has been reported&#x000a0;as a successful treatment for severe diphenhydramine overdose refractory to other interventions.<xref ref-type="bibr" rid="article-30306.r34">[34]</xref></p>
        <p>Alternatives to physostigmine are rivastigmine and pyridostigmine. Rivastigmine is only available in oral and transdermal formulations. Pyridostigmine is available in an oral and intravenous formulations. Neither has FDA approval for this indication.</p>
      </sec>
      <sec id="article-30306.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Many conditions can cause agitated delirium, especially in the elderly. Side effects of other medications and polypharmacy should be considered. Meningitis, sepsis, uremia, sympathomimetic toxicity, salicylate toxicity, and serotonin syndrome can all present similarly to anticholinergic poisoning.<xref ref-type="bibr" rid="article-30306.r35">[35]</xref> Pure anticholinergic toxicity versus mixed toxicity,&#x000a0;as seen with tricyclic antidepressants and phenothiazines, should be considered.</p>
      </sec>
      <sec id="article-30306.s11" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Overall, with early identification and adequate supportive care, the prognosis of anticholinergic toxicity is good.</p>
      </sec>
      <sec id="article-30306.s12" sec-type="Complications">
        <title>Complications</title>
        <list list-type="bullet">
          <list-item>
            <p>Respiratory failure</p>
          </list-item>
          <list-item>
            <p>Cardiovascular collapse</p>
          </list-item>
          <list-item>
            <p>Rhabdomyolysis</p>
          </list-item>
          <list-item>
            <p>Seizures</p>
          </list-item>
          <list-item>
            <p>Coma</p>
          </list-item>
          <list-item>
            <p>Permanent disability</p>
          </list-item>
          <list-item>
            <p>Death</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30306.s13" sec-type="Consultations">
        <title>Consultations</title>
        <p>Depending on the severity, the following consults may be indicated:</p>
        <list list-type="bullet">
          <list-item>
            <p>Poison Control can be reached 24 hours a day in the United States at 1-800-222-1222.</p>
          </list-item>
          <list-item>
            <p>Intensivist for intensive care unit&#x000a0;(ICU) admission</p>
          </list-item>
          <list-item>
            <p>Psychiatry if the ingestion was intentional self-harm</p>
          </list-item>
          <list-item>
            <p>Nephrology, if dialysis&#x000a0;is necessary</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30306.s14" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients taking multiple medications should be educated that anticholinergic side effects are common. Parents and guardians should be encouraged to keep all medications in a safe place, inaccessible to children. This includes over-the-counter medications in addition to prescription medications. All patients should be informed not to take their medications more frequently than prescribed and not to take more than the recommended dose of over-the-counter medications. Patients should also be counseled not to drive after taking sedating anticholinergics such as antihistamines.</p>
      </sec>
      <sec id="article-30306.s15" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <list list-type="bullet">
          <list-item>
            <p>Always consider anticholinergic toxicity in patients taking multiple medications, especially older patients.</p>
          </list-item>
          <list-item>
            <p>Always consider anticholinergic toxicity in young children who present somnolent or lethargic.</p>
          </list-item>
          <list-item>
            <p>Remember the mnemonic "red as a beet, dry as a bone, blind as a bat, mad as a hatter, hot as a hare, full as a flask."</p>
          </list-item>
          <list-item>
            <p>Confirmatory testing is not usually readily available in the emergency setting. Anticholinergic toxicity is a clinical diagnosis.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-30306.s16" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The prevention and treatment of anticholinergic toxicity can be maximized by adopting an interprofessional team-based approach. This interprofessional team will include clinicians, mid-level practitioners, nurses, pharmacists, and any needed specialists. Psychiatry services should see any patient with anticholinergic poisoning&#x000a0;as an inpatient and refer to outpatient behavioral health resources if the ingestion is&#x000a0;due to intentional self-harm. Pharmacists in the hospital and the community are excellent resources for educating patients and the community regarding medication side effects, dosage, and synergistic effects of taking more than one anticholinergic agent. In many emergency departments, pharmacists perform routine reconciliation of patients&#x02019; home medications. Thus, pharmacists have a prime opportunity to recognize and alert providers of potential drug interactions, which would place a patient at higher risk for anticholinergic toxicity. Both nursing staff and pharmacy staff can play an increased role in patient education at the time of discharge from the hospital regarding the appropriate&#x000a0;consumption of anticholinergic drugs. Nursing staff should also assist in educating all patients on anticholinergic agents and stress the importance of keeping them out of the reach of children. Prehospital providers can also aid clinicians in making the diagnosis of anticholinergic poisoning by interviewing bystanders and observing the scene for any medications or substances that may have been available to the patient.<xref ref-type="bibr" rid="article-30306.r36">[36]</xref><xref ref-type="bibr" rid="article-30306.r37">[37]</xref><xref ref-type="bibr" rid="article-30306.r38">[38]</xref><xref ref-type="bibr" rid="article-30306.r39">[39]</xref>&#x000a0;[Level&#x000a0;5]</p>
      </sec>
      <sec id="article-30306.s17">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=30306&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=30306">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/medications/anticholinergic-toxicity/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=30306">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/30306/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=30306">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-30306.s18">
        <title>References</title>
        <ref id="article-30306.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Zimmerman</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Schauben</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>2015 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 33rd Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>54</volume>
            <issue>10</issue>
            <fpage>924</fpage>
            <page-range>924-1109</page-range>
            <pub-id pub-id-type="pmid">28004588</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Dyer</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Shannon</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Powers</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>1997 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</article-title>
            <source>Am J Emerg Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>443</fpage>
            <page-range>443-97</page-range>
            <pub-id pub-id-type="pmid">9725964</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cobaugh</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Youniss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Omslaer</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Drab</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Benson</surname>
                <given-names>BE</given-names>
              </name>
            </person-group>
            <article-title>2000 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</article-title>
            <source>Am J Emerg Med</source>
            <year>2001</year>
            <month>Sep</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>337</fpage>
            <page-range>337-95</page-range>
            <pub-id pub-id-type="pmid">11555795</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Watson</surname>
                <given-names>WA</given-names>
              </name>
              <name>
                <surname>Litovitz</surname>
                <given-names>TL</given-names>
              </name>
              <name>
                <surname>Klein-Schwartz</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Youniss</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reid</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rouse</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Rembert</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Borys</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>2003 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System.</article-title>
            <source>Am J Emerg Med</source>
            <year>2004</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>5</issue>
            <fpage>335</fpage>
            <page-range>335-404</page-range>
            <pub-id pub-id-type="pmid">15490384</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Smulyan</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>The Beat Goes On: The Story of Five Ageless Cardiac Drugs.</article-title>
            <source>Am J Med Sci</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>356</volume>
            <issue>5</issue>
            <fpage>441</fpage>
            <page-range>441-450</page-range>
            <pub-id pub-id-type="pmid">30055757</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Feinberg</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The problems of anticholinergic adverse effects in older patients.</article-title>
            <source>Drugs Aging</source>
            <year>1993</year>
            <season>Jul-Aug</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>335</fpage>
            <page-range>335-48</page-range>
            <pub-id pub-id-type="pmid">8369593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tune</surname>
                <given-names>LE</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic effects of medication in elderly patients.</article-title>
            <source>J Clin Psychiatry</source>
            <year>2001</year>
            <volume>62 Suppl 21</volume>
            <fpage>11</fpage>
            <page-range>11-4</page-range>
            <pub-id pub-id-type="pmid">11584981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vanderhoff</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Mosser</surname>
                <given-names>KH</given-names>
              </name>
            </person-group>
            <article-title>Jimson weed toxicity: management of anticholinergic plant ingestion.</article-title>
            <source>Am Fam Physician</source>
            <year>1992</year>
            <month>Aug</month>
            <volume>46</volume>
            <issue>2</issue>
            <fpage>526</fpage>
            <page-range>526-30</page-range>
            <pub-id pub-id-type="pmid">1636566</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tiongson</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Salen</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Mass ingestion of Jimson Weed by eleven teenagers.</article-title>
            <source>Del Med J</source>
            <year>1998</year>
            <month>Nov</month>
            <volume>70</volume>
            <issue>11</issue>
            <fpage>471</fpage>
            <page-range>471-6</page-range>
            <pub-id pub-id-type="pmid">9846457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Weiner</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Bayer</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>McKay</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>DeMeo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Starr</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Anticholinergic poisoning with adulterated intranasal cocaine.</article-title>
            <source>Am J Emerg Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>517</fpage>
            <page-range>517-20</page-range>
            <pub-id pub-id-type="pmid">9725971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ridder</surname>
                <given-names>WP</given-names>
              </name>
              <name>
                <surname>Klimek</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rupreht</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>[Physostigmine for the immediate treatment of a patient with the central anticholinergic syndrome induced by cocaine cut with atropine].</article-title>
            <source>Ned Tijdschr Geneeskd</source>
            <year>2005</year>
            <month>Jul</month>
            <day>23</day>
            <volume>149</volume>
            <issue>30</issue>
            <fpage>1701</fpage>
            <page-range>1701-3</page-range>
            <pub-id pub-id-type="pmid">16104118</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hamilton</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Perrone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Henretig</surname>
                <given-names>FM</given-names>
              </name>
              <name>
                <surname>Karkevandian</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Marcus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>RD</given-names>
              </name>
              <name>
                <surname>Blok</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nordenholz</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>A descriptive study of an epidemic of poisoning caused by heroin adulterated with scopolamine.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2000</year>
            <volume>38</volume>
            <issue>6</issue>
            <fpage>597</fpage>
            <page-range>597-608</page-range>
            <pub-id pub-id-type="pmid">11185966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Reilly</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Weisse</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Topically induced diphenhydramine toxicity.</article-title>
            <source>J Emerg Med</source>
            <year>1990</year>
            <season>Jan-Feb</season>
            <volume>8</volume>
            <issue>1</issue>
            <fpage>59</fpage>
            <page-range>59-61</page-range>
            <pub-id pub-id-type="pmid">2351800</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bernhardt</surname>
                <given-names>DT</given-names>
              </name>
            </person-group>
            <article-title>Topical diphenhydramine toxicity.</article-title>
            <source>Wis Med J</source>
            <year>1991</year>
            <month>Aug</month>
            <volume>90</volume>
            <issue>8</issue>
            <fpage>469</fpage>
            <page-range>469-71</page-range>
            <pub-id pub-id-type="pmid">1926887</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gummin</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Mowry</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Spyker</surname>
                <given-names>DA</given-names>
              </name>
              <name>
                <surname>Brooks</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Fraser</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Banner</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>2016 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 34th Annual Report.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>55</volume>
            <issue>10</issue>
            <fpage>1072</fpage>
            <page-range>1072-1252</page-range>
            <pub-id pub-id-type="pmid">29185815</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mitchelson</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptor agonists and antagonists: effects on ocular function.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2012</year>
            <issue>208</issue>
            <fpage>263</fpage>
            <page-range>263-98</page-range>
            <pub-id pub-id-type="pmid">22222703</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Harvey</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic receptor agonists and antagonists: effects on cardiovascular function.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2012</year>
            <issue>208</issue>
            <fpage>299</fpage>
            <page-range>299-316</page-range>
            <pub-id pub-id-type="pmid">22222704</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ehlert</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Pak</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MT</given-names>
              </name>
            </person-group>
            <article-title>Muscarinic agonists and antagonists: effects on gastrointestinal function.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2012</year>
            <issue>208</issue>
            <fpage>343</fpage>
            <page-range>343-74</page-range>
            <pub-id pub-id-type="pmid">22222706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scavone</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Greenblatt</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Harmatz</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Engelhardt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shader</surname>
                <given-names>RI</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics of diphenhydramine 25 mg in young and elderly volunteers.</article-title>
            <source>J Clin Pharmacol</source>
            <year>1998</year>
            <month>Jul</month>
            <volume>38</volume>
            <issue>7</issue>
            <fpage>603</fpage>
            <page-range>603-9</page-range>
            <pub-id pub-id-type="pmid">9702844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Renner</surname>
                <given-names>UD</given-names>
              </name>
              <name>
                <surname>Oertel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kirch</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and pharmacodynamics in clinical use of scopolamine.</article-title>
            <source>Ther Drug Monit</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-65</page-range>
            <pub-id pub-id-type="pmid">16175141</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ali-Melkkil&#x000e4;</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kanto</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Iisalo</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetics and related pharmacodynamics of anticholinergic drugs.</article-title>
            <source>Acta Anaesthesiol Scand</source>
            <year>1993</year>
            <month>Oct</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>633</fpage>
            <page-range>633-42</page-range>
            <pub-id pub-id-type="pmid">8249551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holstege</surname>
                <given-names>CP</given-names>
              </name>
              <name>
                <surname>Borek</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Toxidromes.</article-title>
            <source>Crit Care Clin</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>28</volume>
            <issue>4</issue>
            <fpage>479</fpage>
            <page-range>479-98</page-range>
            <pub-id pub-id-type="pmid">22998986</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Tsai</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Hung</surname>
                <given-names>DZ</given-names>
              </name>
              <name>
                <surname>Hu</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Deng</surname>
                <given-names>JF</given-names>
              </name>
            </person-group>
            <article-title>Common toxidromes of plant poisonings in Taiwan.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2009</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>161</fpage>
            <page-range>161-8</page-range>
            <pub-id pub-id-type="pmid">18788001</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thakur</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Aslam</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Aslam</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Vasavada</surname>
                <given-names>BC</given-names>
              </name>
              <name>
                <surname>Sacchi</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>IA</given-names>
              </name>
            </person-group>
            <article-title>QT interval prolongation in diphenhydramine toxicity.</article-title>
            <source>Int J Cardiol</source>
            <year>2005</year>
            <month>Feb</month>
            <day>15</day>
            <volume>98</volume>
            <issue>2</issue>
            <fpage>341</fpage>
            <page-range>341-3</page-range>
            <pub-id pub-id-type="pmid">15686790</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharma</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Hexdall</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Chang</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Hoffman</surname>
                <given-names>RS</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine-induced wide complex dysrhythmia responds to treatment with sodium bicarbonate.</article-title>
            <source>Am J Emerg Med</source>
            <year>2003</year>
            <month>May</month>
            <volume>21</volume>
            <issue>3</issue>
            <fpage>212</fpage>
            <page-range>212-5</page-range>
            <pub-id pub-id-type="pmid">12811715</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Derinoz</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Emeksiz</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Use of physostigmine for cyclopentolate overdose in an infant.</article-title>
            <source>Pediatrics</source>
            <year>2012</year>
            <month>Sep</month>
            <volume>130</volume>
            <issue>3</issue>
            <fpage>e703</fpage>
            <page-range>e703-5</page-range>
            <pub-id pub-id-type="pmid">22908101</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bross</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Nash</surname>
                <given-names>BT</given-names>
              </name>
              <name>
                <surname>Carlton</surname>
                <given-names>FB</given-names>
              </name>
            </person-group>
            <article-title>Heat emergencies.</article-title>
            <source>Am Fam Physician</source>
            <year>1994</year>
            <month>Aug</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>389</fpage>
            <page-range>389-96, 398</page-range>
            <pub-id pub-id-type="pmid">8042574</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Green</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sitar</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Tenenbein</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Effect of anticholinergic drugs on the efficacy of activated charcoal.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>2004</year>
            <volume>42</volume>
            <issue>3</issue>
            <fpage>267</fpage>
            <page-range>267-72</page-range>
            <pub-id pub-id-type="pmid">15362593</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Isbister</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Kumar</surname>
                <given-names>VV</given-names>
              </name>
            </person-group>
            <article-title>Indications for single-dose activated charcoal administration in acute overdose.</article-title>
            <source>Curr Opin Crit Care</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>17</volume>
            <issue>4</issue>
            <fpage>351</fpage>
            <page-range>351-7</page-range>
            <pub-id pub-id-type="pmid">21716104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Holger</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Harris</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Engebretsen</surname>
                <given-names>KM</given-names>
              </name>
            </person-group>
            <article-title>Physostigmine, sodium bicarbonate, or hypertonic saline to treat diphenhydramine toxicity.</article-title>
            <source>Vet Hum Toxicol</source>
            <year>2002</year>
            <month>Feb</month>
            <volume>44</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-4</page-range>
            <pub-id pub-id-type="pmid">11824763</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arens</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Al-Abri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Olson</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Kearney</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Safety and effectiveness of physostigmine: a 10-year retrospective review&#x0003c;sup/&#x0003e;.</article-title>
            <source>Clin Toxicol (Phila)</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>56</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-107</page-range>
            <pub-id pub-id-type="pmid">28703024</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rosenbaum</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bird</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Timing and frequency of physostigmine redosing for antimuscarinic toxicity.</article-title>
            <source>J Med Toxicol</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>6</volume>
            <issue>4</issue>
            <fpage>386</fpage>
            <page-range>386-92</page-range>
            <pub-id pub-id-type="pmid">20405266</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pentel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Peterson</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Asystole complicating physostigmine treatment of tricyclic antidepressant overdose.</article-title>
            <source>Ann Emerg Med</source>
            <year>1980</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>11</issue>
            <fpage>588</fpage>
            <page-range>588-90</page-range>
            <pub-id pub-id-type="pmid">7001962</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdelmalek</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Schwarz</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Sampson</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Halcomb</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>McCammon</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Arroyo-Plasencia</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Stenger</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Krehbiel</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mullins</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>Life-threatening diphenhydramine toxicity presenting with seizures and a wide complex tachycardia improved with intravenous fat emulsion.</article-title>
            <source>Am J Ther</source>
            <year>2014</year>
            <season>Nov-Dec</season>
            <volume>21</volume>
            <issue>6</issue>
            <fpage>542</fpage>
            <page-range>542-4</page-range>
            <pub-id pub-id-type="pmid">24096706</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perrone</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Stecker</surname>
                <given-names>MM</given-names>
              </name>
            </person-group>
            <article-title>Viral encephalitis masquerading as a fulminant anticholinergic toxidrome.</article-title>
            <source>J Toxicol Clin Toxicol</source>
            <year>1997</year>
            <volume>35</volume>
            <issue>6</issue>
            <fpage>627</fpage>
            <page-range>627-33</page-range>
            <pub-id pub-id-type="pmid">9365431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Thomas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nallur</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Deslandes</surname>
                <given-names>PN</given-names>
              </name>
            </person-group>
            <article-title>Diphenhydramine abuse and detoxification: a brief review and case report.</article-title>
            <source>J Psychopharmacol</source>
            <year>2009</year>
            <month>Jan</month>
            <volume>23</volume>
            <issue>1</issue>
            <fpage>101</fpage>
            <page-range>101-5</page-range>
            <pub-id pub-id-type="pmid">18308811</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grande</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Tramacere</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Vetrano</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Clerici</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pomati</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mariani</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Filippini</surname>
                <given-names>G</given-names>
              </name>
              <collab>REMIND Study Group (Rete Milanese Integrata per le Demenze)</collab>
            </person-group>
            <article-title>Role of anticholinergic burden in primary care patients with first cognitive complaints.</article-title>
            <source>Eur J Neurol</source>
            <year>2017</year>
            <month>Jul</month>
            <volume>24</volume>
            <issue>7</issue>
            <fpage>950</fpage>
            <page-range>950-955</page-range>
            <pub-id pub-id-type="pmid">28503836</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Balling</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Erstad</surname>
                <given-names>BL</given-names>
              </name>
              <name>
                <surname>Weibel</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Impact of a transition-of-care pharmacist during hospital discharge.</article-title>
            <source>J Am Pharm Assoc (2003)</source>
            <year>2015</year>
            <season>Jul-Aug</season>
            <volume>55</volume>
            <issue>4</issue>
            <fpage>443</fpage>
            <page-range>443-8</page-range>
            <pub-id pub-id-type="pmid">26161488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-30306.r39">
          <label>39</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Borowy</surname>
                <given-names>CS</given-names>
              </name>
              <name>
                <surname>Mukherji</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <chapter-title>Antihistamine Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>4</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29493943</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
